
Neuren Pharmaceuticals extends trofinetide patent to 2041
- Acadia Pharmaceuticals received a notice of allowance for a patent covering the weight-banded dosing of trofinetide.
- The Neuren share price traded lower to $20.21 following the intellectual property update.
- Neuren stated the new patent is expected to provide US market protection until March 2041.
Neuren Pharmaceuticals (ASX:NEU) announced partner Acadia Pharmaceuticals (NASDAQ:ACAD) secured a US patent allowance extending trofinetide protections.
The new patent extends exclusivity by almost five years beyond the previous use patent expiring in July 2036.
The pending patent covers the weight-banded dosing regimen for the Rett syndrome drug DAYBUE.
Neuren stated the patent is expected to issue after standard administrative steps and a paediatric exclusivity period.
The company stated the issuance is expected to prolong market protection.
Following the announcement, the Neuren Pharmaceuticals share price was down at $20.21.
The business focuses on developing orally administered therapies for serious neurological disorders with limited approved treatments.
Neuren is also advancing ercanetide for multiple neurodevelopmental disorders under US orphan drug designations.
Frequently asked questions
More from Australia
Verity Resources receives approval for 10m Botswana exploration pits
Frasers urges Accent chairman to resign after 1.9% sales drop
American Rare Earths completes 2,879.6-metre Halleck Creek drilling
First Graphene signs 100-country composites deal
Dreadnought Resources starts 15-hole gold drilling program
Grand Gulf Energy secures 8,750km2 in Kazakhstan
